The long-term goal of this work is to improve human health by enabling the discovery of disease-causing mutations. Many human diseases, including cancer, are ultimately caused by mutations in specific genes. Discovery of these genes is a critical step in improving detection and diagnosis of disease, as well as for the design of molecularly-based, targeted therapies. However, disease gene discovery is hampered by the difficulties of working with human populations and by the low penetrance of many disease-causing alleles. To improve disease gene discovery, we are using the zebrafish, an excellent model of human diseases including cancer, microbial pathogenesis and birth defects. Previously, we used forward genetic screens to identify gene mutations that cause increased cancer susceptibility in zebrafish. We and others have also shown that transgenic expression of specific human disease alleles makes zebrafish susceptible to the relevant human disease. These """"""""susceptibility strains"""""""" generally require a """"""""second hit""""""""-a mutation at a specific locus-to manifest disease, and thus could be an invaluable resource for identifying critical disease- modifying genes in human disease. Progress in using the susceptibility strains for gene discovery is hampered by the low penetrance and long latency of disease, and by the lack of zebrafish models for epithelial cancers, the most common cancers in humans. We have successfully used haplotype mapping to identify a low-penetrance, adult onset disease gene causing testicular tumors in zebrafish. Here we propose to establish a robust, user-friendly haplotype mapping panel as a resource for the entire zebrafish community. Taking advantage of this panel and the zebrafish separase cancer-susceptibility strain, we will identify novel gene mutations responsible for epithelial carcinogenesis. The availability of haplotype mapping methods and these epithelial cancer strains will significantly expand the power of the zebrafish for human disease research.
More than half a million people die of cancer each year in the US, and better treatments are needed. To discover the genes mutated in cancers and allow the development of more effective therapies, we are using the genetic vertebrate model system, the zebrafish. In this proposal we describe methods to significantly increase the efficiency of cancer gene discovery in zebrafish and the generation of zebrafish that accurately model human cancers.
|Tiwari, Bhavana; Kurtz, Paula; Jones, Amanda E et al. (2017) Retrotransposons Mimic Germ Plasm Determinants to Promote Transgenerational Inheritance. Curr Biol 27:3010-3016.e3|
|Lee, Eunmyong; Wei, Yongjie; Zou, Zhongju et al. (2016) Genetic inhibition of autophagy promotes p53 loss-of-heterozygosity and tumorigenesis. Oncotarget 7:67919-67933|
|Wylie, Annika; Jones, Amanda E; D'Brot, Alejandro et al. (2016) p53 genes function to restrain mobile elements. Genes Dev 30:64-77|
|Frazier, A Lindsay; Hale, Juliet P; Rodriguez-Galindo, Carlos et al. (2015) Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol 33:195-201|
|Lee, Eunmyong; Koo, Yeon; Ng, Aylwin et al. (2014) Autophagy is essential for cardiac morphogenesis during vertebrate development. Autophagy 10:572-87|
|Rakheja, Dinesh; Chen, Kenneth S; Liu, Yangjian et al. (2014) Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802|
|Rodriguez-Galindo, Carlos; Krailo, Mark; Frazier, Lindsay et al. (2013) Children's Oncology Group's 2013 blueprint for research: rare tumors. Pediatr Blood Cancer 60:1016-21|
|Amatruda, James F; Ross, Julie A; Christensen, Brock et al. (2013) DNA methylation analysis reveals distinct methylation signatures in pediatric germ cell tumors. BMC Cancer 13:313|
|Chen, Kenneth S; Amatruda, James F (2013) A big catch for germ cell tumour research. PLoS Genet 9:e1003481|
|Wang, Xiaolei; Moon, Jesung; Dodge, Michael E et al. (2013) The development of highly potent inhibitors for porcupine. J Med Chem 56:2700-4|
Showing the most recent 10 out of 22 publications